Category: Intellectual property
-
AbbVie Acquires Coronavirus Antibody Therapy
Drug maker AbbVie is licensing a synthetic antibody to treat Covid-19 and SARS coronaviruses that the company began funding in June.
-
Biotech Licenses Precision Cancer Biologic to Genentech
A biotechnology company discovering synthetic proteins that target cancer-causing genetic mutations is licensing its lead product to biologics maker Genentech.
-
Bayer Gains Lung Cancer Therapy in $670M Deal
Global drug maker Bayer AG is licensing an engineered T-cell therapy to treat mesothelioma and other solid tumor cancers from biotech Atara Biotherapeutics.
-
Stem Cell Respiratory Therapy Licensed in $1.4B Deal
Global drug maker Novartis is acquiring a stem cell-based treatment for a serious respiratory disease associated with Covid-19 infections.
-
Start-Up Gains Drug Nanoparticle Manufacturing Tech
A new enterprise spun-off from University of Connecticut is acquiring a technology for continuous manufacturing of nanoscale drug particles.
-
Novartis Gains Synthetic Protein Therapies for Covid-19
Global drug maker Novartis is gaining access to two Covid-19 therapy candidates made from a library of synthetic protein components.
-
Roche Gains Covid-19 Oral Drug Candidate
Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a oral drug, rather than an infusion.
-
Gene Therapy Delivery Tech Licensed in $1.8B Deal
A biotechnology company creating synthetic viruses with artificial intelligence to deliver gene therapies is licensing its technology to drug maker Roche.
-
Start-Up Gains Access to Vaccine Nasal Spray Technology
A company developing techniques to deliver vaccines like Covid-19 with a nasal spray received an opportunity to license the process from University of Houston.
-
Start-Up Developing Thin Films for Vaccine Delivery
A new enterprise is creating thin films for vaccines, including Covid-19, to make possible their mass production and distribution at room temperatures.